Compare Abbott India with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs NATCO PHARMA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA NATCO PHARMA ABBOTT INDIA/
NATCO PHARMA
 
P/E (TTM) x 47.1 34.0 138.6% View Chart
P/BV x 15.4 4.8 318.4% View Chart
Dividend Yield % 0.4 0.7 64.0%  

Financials

 ABBOTT INDIA   NATCO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
NATCO PHARMA
Mar-19
ABBOTT INDIA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs8,834849 1,040.5%   
Low Rs5,458557 979.8%   
Sales per share (Unadj.) Rs1,731.1573.8 301.7%  
Earnings per share (Unadj.) Rs211.9176.0 120.4%  
Cash flow per share (Unadj.) Rs219.9198.2 110.9%  
Dividends per share (Unadj.) Rs65.006.25 1,040.0%  
Dividend yield (eoy) %0.90.9 102.3%  
Book value per share (Unadj.) Rs945.2842.7 112.2%  
Shares outstanding (eoy) m21.2536.50 58.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.11.2 336.9%   
Avg P/E ratio x33.74.0 844.2%  
P/CF ratio (eoy) x32.53.5 916.2%  
Price / Book Value ratio x7.60.8 906.3%  
Dividend payout %30.73.6 863.7%   
Avg Mkt Cap Rs m151,84825,660 591.8%   
No. of employees `0003.55.0 70.3%   
Total wages/salary Rs m4,3563,559 122.4%   
Avg. sales/employee Rs Th10,555.54,225.3 249.8%   
Avg. wages/employee Rs Th1,249.9718.0 174.1%   
Avg. net profit/employee Rs Th1,292.21,295.9 99.7%   
INCOME DATA
Net Sales Rs m36,78620,945 175.6%  
Other income Rs m1,1331,302 87.0%   
Total revenues Rs m37,91922,247 170.4%   
Gross profit Rs m6,0477,948 76.1%  
Depreciation Rs m169810 20.9%   
Interest Rs m23193 11.7%   
Profit before tax Rs m6,9898,247 84.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4851,823 136.3%   
Profit after tax Rs m4,5036,424 70.1%  
Gross profit margin %16.437.9 43.3%  
Effective tax rate %35.622.1 160.9%   
Net profit margin %12.230.7 39.9%  
BALANCE SHEET DATA
Current assets Rs m27,61023,472 117.6%   
Current liabilities Rs m8,5697,287 117.6%   
Net working cap to sales %51.877.3 67.0%  
Current ratio x3.23.2 100.0%  
Inventory Days Days6092 65.3%  
Debtors Days Days2788 31.1%  
Net fixed assets Rs m1,05718,648 5.7%   
Share capital Rs m213365 58.2%   
"Free" reserves Rs m19,87334,525 57.6%   
Net worth Rs m20,08630,760 65.3%   
Long term debt Rs m00-   
Total assets Rs m29,40943,031 68.3%  
Interest coverage x311.643.7 712.5%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.5 257.0%   
Return on assets %15.415.4 100.1%  
Return on equity %22.420.9 107.4%  
Return on capital %34.927.4 127.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36911,536 3.2%   
Fx outflow Rs m4,9182,939 167.4%   
Net fx Rs m-4,5498,597 -52.9%   
CASH FLOW
From Operations Rs m4,9916,688 74.6%  
From Investments Rs m-2,570-6,122 42.0%  
From Financial Activity Rs m-1,428-509 280.6%  
Net Cashflow Rs m99366 1,505.0%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 7.9 7.8 100.8%  
FIIs % 0.1 16.6 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 26.0 65.8%  
Shareholders   18,270 25,395 71.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 34.5% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 25, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS